Living with advanced-stage follicular lymphoma can be a long journey. For patients with a low tumor burden who do not have symptoms, doctors often weigh the benefits of starting treatment early versus a strategy of watchful waiting. A look at data from 1,590 patients helps clarify what happens when using rituximab alone as a first step.
The analysis found that while rituximab did not significantly improve overall survival or reduce the rate of histological transformation, it did have a clear impact on timing. Specifically, patients who received rituximab were able to go longer before needing to start a new treatment compared to those who were watched closely.
It is important to note that these results come from a small pool of data, including only two randomized controlled trials and one observational study. Because the evidence is limited, these findings show a specific benefit in timing rather than a change in the overall course of the disease.
Common questions
Does rituximab improve survival for patients with follicular lymphoma?
The study of 1,590 patients found no statistically significant difference in overall survival between those who received rituximab and those who were watched closely. While it helped delay the need for new treatments, it did not change the overall survival rate for patients with advanced-stage low-tumor-burden follicular lymphoma.
How does rituximab affect the time before a new treatment is needed?
Rituximab significantly prolonged the time to new treatment compared to watchful waiting. The data showed a hazard ratio of 0.50, meaning patients on rituximab could stay on their current path longer before needing to start a new therapy.
Does rituximab reduce the risk of histological transformation?
The study found that rituximab was not associated with a statistically significant reduction in histological transformation. This means the drug did not significantly lower the risk of the cancer changing into a different type of lymphoma compared to watchful waiting.
